Grazoprevir – 50 mg

Brand:
Cayman
CAS:
1350514-68-9
Storage:
-20
UN-No:
Non-Hazardous - /

Grazoprevir is a pan-genotypic protease inhibitor that binds to hepatitis C virus (HCV) non-structural protein 3/4A (NS3/4A), a serine protease essential for viral replication.{36012} Grazoprevir has potent in vitro activity against major HCV genotypes (Kis = 0.1, 0.1, 0.08, 0.15, and 0.9 nM for genotypes 1a, 1b, 2a, 2b, and 3a, respectively) and common resistance genotypes (Kis = 0.07, 0.14, and 0.30 nM for genotypes 1b R155K, D165V, and D168Y, respectively).  Grazoprevir inhibits the NS3/4A protease in an in vitro replicon system with EC50 values of 2 and 8 nM for genotypes 1a and 2a, respectively. Formulations containing grazoprevir are used in combination therapies to treat HCV.{36013}    

 

Out of stock

SKU: 21816 - Category:

Description

An NS3/4A protease inhibitor; has in vitro activity against major HCV genotypes (Kis = 0.1, 0.1, 0.08, 0.15, and 0.9 nM for genotypes 1a, 1b, 2a, 2b, and 3a, respectively); has in vitro activity against common HCV resistance genotypes (Kis = 0.07, 0.14, and 0.30 for genotypes 1b R155K, D165V, and D168Y, respectively); inhibits the NS3/4A protease in an in vitro replicon system (EC50s = 2 and 8 nM for genotypes 1a and 2a, respectively)


Formal name: (1R,2S)-N-[[[(1R,2R)-2-[5-(3-hydroxy-6-methoxy-2-quinoxalinyl)pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-hydroxy-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, cyclic (1→2)-ether

Synonyms:  MK-5172

Molecular weight: 766.9

CAS: 1350514-68-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals|Protease Inhibitors||Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Hepatitis